

In re Application of:

Serial No.

Filing Date

Title

TREATMENT OF ERECTILE DYSFUNCTION

Examiner

Unassigned

Group Art Unit

1614

Assistant Commissioner of Patents Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08A. A copy of each of the references listed on the attached form is submitted herewith.

It is respectfully requested that the references listed on the attached form be expressly considered by the Examiner and be made of record in the application and appear among the "References Cited" on any patent to issue therefrom.

References listed herein include one Bulgarian patent application, and three Japenese patent applications.

Based on the English language version of the abstract, Bulgarian patent application BG103246 appears to describe the use of Rho kinase inhibitors as a means of treatment of hypertension, angina pectoris, asthma, disease of circulation to peripheral organs, atherosclerosis, cancer, inflammatory processes, autoimmune processes, AIDS, osteoporosis, retinopathy, and to improve brain function. BG103246 also describes that Rho kinase inhibitors suppress cardiovascular contractions, prevent premature birth, and prevents infections of the gastrointestinal tract. A full English translation of BG103246 is not readily available.

Based on the English version of the abstract, JP704825 A2 describes a formulation for preventing emesis and treating sexual dysfunction using a compound containing tetrahydrobenz(cd)indole-6-carboxamide such as 4-dipropylamino-1,3,4,5tetrhydrobenz(cd)indole-6-carboxamide, as the active ingredient. These compounds are chemically distinct from the Rho kinase inhibitors described in the above-cited application. This patent appears to be closely related (same family) to EP 0633023 (see web printout attached to both). A full English translation of JP704825 A2 is not readily available.

Based on the English version of the abstract, WO98/06433 describes medicine comprising Rho kinase inhibitors, such as hypertension remedy, angina remedy, cerebrovascular twitching inhibitor, asthma remedy, premature birth preventive, arteriosclerosis remedy, anticancer drug, anti-phlogistic, immunosuppressive, autoimmune disease remedy, anti-AIDs drug, contraceptive, digestive infection preventive, osteoporosis remedy, retinopathy remedy, and cerebral function ameliorants. None of the compounds in WO98/06433 appear to resemble the Rho kinase inhibitor described in the above-cited application. A full English translation of WO98/06433 is not readily available.

Based in the English version of the abstract, WO033845 describes an erectile dysfunction remedy which comprises as the active ingredient a 3(2H)-pyridazinone derivative represented by formula (I) or a pharmacologically acceptable salt thereof. These compounds appear to be chemically distinct from the Rho kinase inhibitors described in the above-cited application. A full English translation of WO033845 is not readily available.

This statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Date: 6/27/02

Cynthia B. Rothschild, Reg. No. 47,040

KILPATRICK STOCKTON LLP 1001 West Fourth Street

Winston-Salem, North Carolina 27101-2400

(336) 747-7541 Phone

(336) 607-7500 Facsimile

Attorney Docket No.: M0351-267875

M0351-267875 WINLIB01:946443.1 (011-00)